(4-氟-3-硝基苯基)甲胺 | 771581-73-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氟-3-硝基苯基)甲胺
• 中文别名: 4-氟-3-硝基苄胺
• 英文名称: (4-Fluoro-3-nitrophenyl)methanamine
• CAS: 771581-73-8
• 化学式: C₇H₇FN₂O₂
• mdl: MFCD06212995
• 分子量: 170.143
• InChiKey: UALXEVNNBBBYCG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4-氟-3-硝基苯基)甲胺 、 4-Chloro-2-(pyridin-3-yl)-5-methyl-thieno-[2,3-d]-pyrimidine 以yields 2-(pyridin-3-yl)-4-(3-nitrobenzylamino)-5-methyl-thieno-[2,3-d]-pyrimidine的产率得到2-(Pyridin-3-yl)-4-(3-nitrobenzylamino)-5-methyl-thieno-[2,3-d]-pyrimidine
  参考文献：
  名称：

  Method for inhibiting neoplastic cells and related conditions by

  摘要：

  苯并噻嘌呤衍生物用于诱导或促进细胞凋亡，阻止不受控制的肿瘤细胞增殖，特别是用于阻止和治疗肿瘤，包括预癌和癌前病变的化合物I：其中R1和R2独立地选择自氢，A，OA，烯基，炔基，--NO2，--CF3或卤素的群，但其中之一不是氢; R3和R4独立地选择自氢，A，--OA，卤素，--NO2，--NH2，--NHA或--NAA'的群，或R3和R4一起形成所选自--O--CH2--CH2--，--O--CH2--O--或--O--CH2--CH2--O的基团; X选择自未取代或取代的5-7成员饱和或不饱和环的群，其中该环选择自苯基，环戊基，环己基，环庚基，呋喃基，二氧杂环戊基，噻吩基，吡咯基，吡咯烷基，咪唑基，吡唑基，吡啶基，哌啶基，吗啉基，吡喃基，二氧杂环己基，吡嗪基，嘧啶基，哌嗪基，喹啉基和异喹啉基，其中“X”环上的取代基中有一或两个选择自较低的烷基，COOH，--COOA，--CONH2，--CONAA'，--CONHA，--CN，--CH2COOH或--CH2CH2COOH的群; A和A'独立地选择自氢或C1-6烷基; n为0、1、2或3; 及其生理上可接受的盐。

  公开号：

  US06133271A1

文献信息

• [EN] 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION<br/>[FR] DÉRIVÉS DE 2-AMINO-BENZIMIDAZOLE UTILES DANS LE TRAITEMENT D'INFLAMMATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012076672A1

  公开（公告）日：2012-06-14

  This invention relates to compounds of formula (I), their use as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), pharmaceutical compositions containing them, and their use as medicaments for the 10 treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R1, R2, R3, R4, R6, R2,R7, R8, R9, Ra, Rb have meanings given in the description.

  本发明涉及公式（I）的化合物，它们作为微体前列腺素E2合酶-1（mPGES-1）的抑制剂的使用，包含它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病及相关状况的药物的使用。A、M、W、R1、R2、R3、R4、R6、R2、R7、R8、R9、Ra、Rb的含义在描述中给出。
• NOVEL COMPOUNDS
  申请人：Priepke Henning

  公开号：US20120309738A1

  公开（公告）日：2012-12-06

  This invention relates to compounds of formula I their use as inhibitors of the microsomal prostaglandin E 2 synthase-1 (mPGES-1), to pharmaceutical compositions containing them, and their use as medicaments for the treatment and/or prevention of inflammatory diseases and associated conditions. A, M, W, R 1 , R 2 , R 3 , R 4 , R 6 , R 2 , R 7 , R 8 , R 9 , R a , R b have meanings given in the description.

  这项发明涉及公式I化合物，它们作为微粒体前列腺素E2合酶-1（mPGES-1）的抑制剂的用途，含有它们的药物组合物，以及它们作为治疗和/或预防炎症性疾病和相关症状的药物的用途。A、M、W、R1、R2、R3、R4、R6、R2、R7、R8、R9、Ra、Rb在描述中有给定的含义。
• [EN] 3H-IMIDAZO [4, 5 -C] PYRIDINE- 6 -CARBOXAMIDES AS ANTI- INFLAMMATORY AGENTS<br/>[FR] 3H-IMIDAZO[4,5-C]PYRIDINE-6-CARBOXAMIDES EN TANT QU'ANTI-INFLAMMATOIRES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010100249A1

  公开（公告）日：2010-09-10

  The present invention relates to compounds of general formula (I) in which A, L, M, Q2, Q3, Q4, R1, R5, Ra, Rb, Rc, W, X, Y, Z1, Z2, Z3 are defined in the description, the salts thereof, particularly the physiologically acceptable salts thereof. The compounds are of potential utility in the treatment and/or prevention of inflammatory diseases and associated conditions, in particular, in the treatment and/or prevention of pain. The invention also relates to the use of such compounds as medicaments, to pharmaceutical compositions containing them, and to their preparation.

  本发明涉及通式(I)中的化合物，其中A、L、M、Q2、Q3、Q4、R1、R5、Ra、Rb、Rc、W、X、Y、Z1、Z2、Z3在描述中有定义，及其盐，特别是其生理上可接受的盐。这些化合物可能在治疗和/或预防炎症性疾病及相关症状方面具有潜在的用途，特别是在治疗和/或预防疼痛方面。本发明还涉及将这些化合物用作药物、含有它们的药物组合物以及它们的制备。
• [EN] ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'ADÉNINE EN TANT QU'INHIBITEURS DE PROTÉINE KINASES
  申请人：BCI PHARMA

  公开号：WO2017191297A1

  公开（公告）日：2017-11-09

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

  本发明涉及一种适用于作为激酶抑制剂的化合物，其符合一般式(I) [化合物(C)，以下简称]，或其N-氧化物、药学上可接受的盐、药学上可接受的溶剂，或其立体异构体，式(I)中A、R1、R2、R3、R3'、R4、R4'、X、Y、Z、T的定义如权利要求所述。本发明还涉及一种体外抑制蛋白激酶活性的方法，包括将蛋白激酶与式(I)的化合物，或其N-氧化物、药学上可接受的盐、药学上可接受的溶剂，或其立体异构体接触。本发明还涉及式(I)的化合物本身，以及其作为药物的用途，以及用于治疗由蛋白激酶介导的疾病的方法，所述疾病包括癌症、炎症性疾病、心血管疾病、病毒感染性疾病、循环系统疾病、纤维增殖性疾病和疼痛敏化性疾病。
• [EN] DEOXYNOJIRIMYCIN DERIVATIVES AS GLUCOSIDASE INHIBITORS<br/>[FR] DÉRIVÉS DE DÉSOXYNOJIRIMYCINE EN TANT QU'INHIBITEURS DE GLUCOSIDASE
  申请人：EMERGENT PRODUCT DEV GAITHERSBURG INC

  公开号：WO2022011211A1

  公开（公告）日：2022-01-13

  The present application provides novel iminosugars and their use as glucosidase inhibitors. The present inventors have discovered that certain deoxynojirimycin derivatives may be effective in inhibiting glucosidases. In particular, such deoxynojirimycin derivatives may be useful for treating a disease or condition where inhibiting glucosidase may be important.

  本申请提供了新颖的亚胺糖以及它们作为葡萄糖苷酶抑制剂的用途。本发明人发现某些脱氧诺吉霉素衍生物可能有效地抑制葡萄糖苷酶。特别是，这些脱氧诺吉霉素衍生物可能对治疗需要抑制葡萄糖苷酶的疾病或病况有用。